In the October 2008 issue, in the article by Benza et al, “Sitaxsentan for the Treatment of Pulmonary Arterial Hypertension: A 1-Year, Prospective, Open-Label Observation of Outcome and Survival” (Chest 2008; 134:775–782), CHEST inadvertently omitted the conflicts of interest statements for the authors. CHEST regrets the omission. They are as follows: Dr. Barst has received grants, been a consultant for and/or has participated in speaking activities for Actelion, Encysive, Gilead, Pfizer, Novartis, United Therapeutics, GlazoSmithKline, and INO. Dr. Galie is an investigator and consultant for Myogen/Gilead. Dr. Frost participated in presentations concerning institutional review board (IRB)-approved multicenter studies on sitaxsentan at both unreimbursed national meetings and continuing medical education conferences, and at pharmaceutical industry-sponsored talks on pulmonary hypertension where data on sitaxsentan were presented solely and also in the context of other pulmonary hypertension (PH)-specific therapies. She was part of advisory boards and scientific leadership committees designed to develop this and future studies on PH, and to disseminate the information derived from IRB-approved, peer-reviewed studies on sitaxsentan and other drugs for the treatment of PH. In addition to Encysive Pharmaceutical, the company developing the drug that was the subject of this article, Dr. Frost has performed the same functions for the following PH-related pharmaceutical companies during the same time frame: Actelion (drugs Tracleer and Ventavis); Gilead (drug Letairis and FLOLAN); United Therapeutics (drug treprostinil/Remodulin); Pfizer (drug Revatio); and Lilly (drug tadalafil). Dr. Girgis has been a consultant to/advisory board member at Gilead (received $10,000 in the last 3 years), Actelion (received $3,000 in the last 3 years), and United Therapeutics (received $2,000 in the last 3 years); has received research support from Lilly-ICOS, Pfizer, Encysive Pharmaceuticals, and Lung Rx; and has been a speaker for Simply Speaking in the PAH Program, which is supported by Gilead Pharmaceuticals. Dr. Highland was a subinvestigator for the STRIDE trials and has served on the speaker's bureau for Encysive Pharmaceuticals. Dr. Strange has been a research investigator for Actelion, Encysive, and Gilead, and has received research support monies. He has been a consultant for and has served on the speaker's bureau for Actelion, Encysive, and Gilead within the past 3 years. Dr. Badesch has received consultant fees from GlaxoSmithKline, Actelion, Myogen/Gilead, Encysive, CoTherix, Pfizer, United Therapeutics, Mondo-Biotech, Biogen IDEC, PR Pharmaceuticals, Forrest Labs, Scios, Amgen, Biovale Pharmaceuticals/Clarus Health, and Johnson & Johnson; has served on the speaker's bureau for GlaxoSmithKline, Actelion, Encysive, Myogen/Gilead, CoTherix, United Therapeutics, and Pfizer; is on advisory committees for GlaxoSmithKline, Actelion, Myogen/Gilead, Encysive, CoTherix, Pfizer, United Therapeutics, Mondo-Biotech, Biogen IDEC; and is on the Pulmonary Hypertension Association Board of Directors, and the American Thoracic Society Board of Directors. Dr. Rubin has received consulting fees from Gilead.